Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Bidder who wrote (25882)	2/8/2000 4:36:00 PM
From: Katie Kommando	Read Replies (1) \| Respond to of 150070

NYSE: HTD . . . I'm looking at it as a 2 week hold until earnings come out. Here is the PR again: Tuesday February 8, 11:50 am Eastern Time Company Press Release Huntingdon Anticipates Strong 1999 Results HUNTINGDON, England--(BUSINESS WIRE)--Feb. 8, 2000--Huntingdon Life Sciences Group plc (NYSE:HTD - news) announced today that it anticipates releasing its 1999 results within the next two weeks. The Company has reported three consecutive quarters of improving revenues and margins, and remains optimistic about the fourth quarter performance of the Group. Responding to the recent decline in the price of the Company's ordinary shares, Brian Cass, Huntingdon's Managing Director, said ``We are aware of nothing in the Company's operating performance nor in its financial condition which would justify the recent weakening in our share price. To the contrary, we are very pleased that our results improved each quarter in 1999, thanks in large part to the continued and increasing support from our clients since the new management team became involved with the Company in September 1998. We are optimistic about the prospects for 2000.' Huntingdon Life Sciences Group plc is one of the world's leading CROs providing product development services to the pharmaceutical, agrochemical and biotechnology industries. Huntingdon brings leading technology and capability to support its clients in non-clinical safety testing of new compounds in early stage development and assessment. Huntingdon operates research facilities in the United Kingdom (Huntingdon and Eye, England) and the United States (The Princeton Research Centre, New Jersey). This announcement contains statements that may be forward-looking as defined by the USA's Private Litigation Reform Act of 1995. These statements are based largely on Huntingdon's expectations and are subject to a number of risks and uncertainties, certain of which are beyond Huntingdon's control, as more fully described in Huntingdon's Form 20-F as filed with the US Securities and Exchange Commission. Contact: Huntingdon Life Sciences Group plc Richard A. Michaelson Phone: UK: +44 (0) 1480 892194